Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Breast Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Breast Neoplasm

Cancer Family

Breast Neoplasm

CI-CAN-00000007Explore in graph →

Non-malignant2,894 active trials43 approved drugs310 evidence items

NCIt: C2910
OncoTree: BNNOS
MeSH: D000069584
MeSH: D001943

Overview
Statistics
Survival
Genomics33
Variants & evidence310
Drugs79
Trials13867
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (268)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 126–150 of 268 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.
· Clin Cancer Res · 2017 · PMID 28679771 · validated civic_curation pubmed
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
· N Engl J Med · 2017 · PMID 28792849 · validated civic_curation pubmed
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas.
· Clin Cancer Res · 2007 · PMID 17947469 · validated civic_curation pubmed
The influence of insulin-like Growth Factor-1-Receptor expression and endocrine treatment on clinical outcome of postmenopausal hormone receptor positive breast cancer patients: A Dutch TEAM substudy analysis.
· Mol Oncol · 2016 · PMID 26706833 · validated civic_curation pubmed
Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
· JCO Precis Oncol · 2025 · PMID 41100773 · validated civic_curation pubmed
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
· Clin Cancer Res · 2006 · PMID 16489069 · validated civic_curation pubmed
Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer.
· Br J Cancer · 1998 · PMID 9569050 · validated

Showing 126–150 of 268 publications

← Previous
1
…
5
6
7
…
11
Next →

civic_curation

Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer.

· Breast Cancer Res Treat · 2013 · PMID 23322234 · validated civic_curation pubmed

Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.

· Ann Oncol · 2006 · PMID 16497822 · validated civic_curation pubmed

Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.

· Int J Oncol · 2012 · PMID 22842582 · validated civic_curation pubmed

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

· J Clin Oncol · 2010 · PMID 20142587 · validated civic_curation pubmed

TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer.

· Endocr Relat Cancer · 2015 · PMID 25900183 · validated civic_curation pubmed

RSF1 and not cyclin D1 gene amplification may predict lack of benefit from adjuvant tamoxifen in high-risk pre-menopausal women in the MA.12 randomized clinical trial.

· PLoS One · 2013 · PMID 24367492 · validated civic_curation pubmed

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer.

· Br J Cancer · 2006 · PMID 16404430 · validated civic_curation pubmed

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.

· Breast Cancer Res Treat · 2012 · PMID 22418700 · validated civic_curation pubmed

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.

· Lancet Oncol · 2015 · PMID 26596672 · validated civic_curation pubmed

Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer.

· Clin Cancer Res · 2015 · PMID 25370464 · validated civic_curation pubmed

ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.

· Oncology · 2012 · PMID 22906996 · validated civic_curation pubmed

MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.

· Oncotarget · 2016 · PMID 26921265 · validated civic_curation pubmed

Penetrance analysis of the PALB2 c.1592delT founder mutation.

· Clin Cancer Res · 2008 · PMID 18628482 · validated civic_curation pubmed

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

· Am J Pathol · 2010 · PMID 20813970 · validated civic_curation pubmed

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

· J Clin Oncol · 2013 · PMID 23382472 · validated civic_curation pubmed

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.

· Cancer Cell · 2014 · PMID 25002028 · validated civic_curation pubmed

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.

· J Clin Oncol · 2015 · PMID 25847936 · validated civic_curation pubmed

PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition.

· Cancer Cell · 2016 · PMID 27451907 · validated civic_curation pubmed